Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

INO Inovio Pharmaceuticals, Inc.
$1.69 -1.48% -0.02
Notify me if price changes either direction
Interactive Brokers Logotype

Buy INO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 116.1M
Enterprise value 48.1M
Trailing PE -0.43037974683544
Forward PE -1.1416781
PEG Ratio 0.19151898734177
Enterprise to EBITDA -0.546
Enterprise to revenue 264.05
Price to book MRQ -11.487959070344
Price to sales TTM 625.477

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 182.3K
EBITDA -88220528
Diluted EPS TTM -2.72
Total Cash (MRQ) 50.8M
Current ratio (MRQ) 0.79
Operating Cash Flow (TTM) -88922792

INO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent INO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.